Breed · Dog

Pomeranian: adverse event reports

FDA breed label "Spitz - German Pomeranian" · single-breed animals only

Read this first · FDA's caveat, in its words

An API dataset query result cannot be used to estimate the risk associated with the product or compare one drug or device product with another. When looking at the results, be aware that there is no certainty that the reported drug or device caused the adverse event. This dataset should not be the sole source of information for clinical decision-making or other assumptions about the safety or effectiveness of a product. The adverse event may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources. FDA Center for Veterinary Medicine

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

Not veterinary advice. This site lists what was reported to FDA. For an animal that is unwell, contact a veterinarian.

9,097reports, 1987–20260.9% of dog reports

372reports, 12 months to March 2026320 in the 12 months before

38%classed serious, as reportedall dogs: 38.3%

15.3%name milbemycin oxime + spinosadall dogs: 13.1%

9,097 adverse event reports received by FDA describe an animal recorded as Pomeranian (FDA breed label "Spitz - German Pomeranian"). That is 0.9% of all reports about dogs. Crossbred animals are not counted here, only reports that give this single breed.

372 reports arrived in the 12 months to March 2026, up 16% from 320 in the 12 months before. A breed's count mostly mirrors how common the breed is; registration and ownership figures by breed are not public data, so no per-animal rate can be given.

By active ingredient, the drugs named most often are milbemycin oxime + spinosad, spinosad and ivermectin + pyrantel pamoate. Milbemycin Oxime + Spinosad is named in 15.3% of this breed's reports, about the same share as in reports about all dogs (13.1%).

The terms listed most often are vomiting (23.3%), lethargy (11.1%) and lack of efficacy (ectoparasite) - flea (9.9%). Vomiting appears in 23.3% of reports, about the same share as in all dog reports (19.7%). 38% of reports stating seriousness were classed as serious, against 38.3% for dogs overall.

Drugs named most often, by active ingredient

Active ingredients recorded for the drug	Reports	Share of Pomeranian reports	Share of all dog reports
Milbemycin Oxime + Spinosad	1,389	15.3%	13.1%
Spinosad	1,200	13.2%	5.8%
Ivermectin + Pyrantel Pamoate	832	9.1%	14.9%
Fluralaner	718	7.9%	6.7%
Afoxolaner	454	5%	5.7%
Selamectin	379	4.2%	3%
Moxidectin	352	3.9%	5%
Pyrantel Pamoate + Sarolaner	301	3.3%	5.1%
Carprofen	253	2.8%	4.8%
Milbemycin Oxime	227	2.5%	3%
Nitenpyram	223	2.5%	1.1%
Lufenuron + Milbemycin Oxime	206	2.3%	2.7%
Maropitant	181	2%	1.2%
Imidacloprid + Moxidectin	176	1.9%	1.3%
Sarolaner	172	1.9%	1.7%
Meloxicam	168	1.8%	0.8%
Milbemycin Oxime + Praziquantel	148	1.6%	3.1%
Pimobendan	141	1.5%	0.6%
(S) - methoprene	132	1.5%	0.6%
Insulin	128	1.4%	0.7%

Ordered by report count. Differences from the species column often come from body size (which drugs a breed is prescribed) and from how common the breed was in the years a drug sold most. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.

Signs listed in reports

share of Pomeranian reports listing the termall dog reports

Vomiting23.3%2,116
Lethargy[unusually tired or inactive]11.1%1,008
Lack of efficacy (ectoparasite) - flea[the product did not have the expected effect: fleas]9.9%901
Emesis[vomiting]8.5%774
Diarrhoea[diarrhea]8%729
Anorexia[not eating]5.9%541
Depression[dull, quiet or withdrawn]5.8%524
Seizure NOS[seizure, type not specified]5.1%462
Death4.4%400
Ataxia[unsteady, uncoordinated movement]3.9%351
Lack of efficacy - NOS[the product did not have the expected effect]3.5%316
Behavioural disorder NOS[behaviour change, type not specified]2.6%235
Accidental exposure[exposure that was not intended]2.5%224
Pruritus[itching]2.3%213
Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]2.3%212
Lack of efficacy (endoparasite) - hookworm[the product did not have the expected effect: hookworms]2.3%211
Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]2.2%201
Emesis (multiple)[vomiting more than once]2.2%200
Ineffective, heartworm larvae[legacy FDA term: the product did not have the expected effect (heartworm larvae)]2.2%199
Trembling2.1%192
Shaking2.1%190
Not eating2.1%188
Other abnormal test result NOS[abnormal laboratory result, type not specified]1.9%171
Convulsion[seizure]1.9%170
Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]1.9%170

Age and weight

Age of the animal

Under 1 year10.8%980

1 to 3 years25.1%2,280

4 to 7 years26.7%2,425

8 to 11 years20.9%1,903

12 years and over13.1%1,193

Age not given3.5%316

Weight of the animal

Under 5 kg (11 lb)59.2%5,386

5 to 9.9 kg (11–22 lb)34.4%3,131

10 to 24.9 kg (22–55 lb)2.6%240

25 to 44.9 kg (55–99 lb)0%3

45 kg and over (99 lb+)0%0

Weight not given3.7%337

Coloured bar: Pomeranian reports. Grey bar: all dog reports.

Trend and outcomes

Reports by month FDA received them. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Outcome recorded in the report

Recovered/Normal29.1%2,645

Recovered with Sequela3.1%283

Ongoing15.5%1,410

Died5.2%472

Euthanized1.3%114

Outcome Unknown22.4%2,039

Beside all dogs

Measure	Pomeranian	All dogs
Reports	9,097	985,675
Latest 12 months	372	53,292
Classed serious, of reports stating it	38%	38.3%
Death or euthanasia recorded, per 1,000 reports	64.4	55

Questions about Pomeranian reports

How many FDA adverse event reports involve Pomeranians?

9,097 reports through March 2026, 0.9% of reports about dogs; 372 in the latest 12 months.

Which drugs are named most often in Pomeranian reports?

By active ingredient: milbemycin oxime + spinosad (1,389), spinosad (1,200), ivermectin + pyrantel pamoate (832), fluralaner (718) and afoxolaner (454). Brands are masked in the public data.

What signs are reported most for this breed?

vomiting (23.3%), lethargy (11.1%), lack of efficacy (ectoparasite) - flea (9.9%), emesis (8.5%) and diarrhoea (8%).

Is the Pomeranian more sensitive to certain drugs?

Report counts cannot answer that. They show what was reported, not what a drug did, and they are not adjusted for how many Pomeranian animals exist or were treated. Breed-related drug sensitivities that are established are described on FDA-approved labels; a veterinarian is the person to ask about an individual animal.

Why are crossbreds not included?

FDA records crossbred animals with one or more component breeds. Counting them under each component would double count, so breed pages use single-breed reports only. Crossbreds remain in the species totals.

How do I report a problem?

Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Breed names are FDA's labels rearranged into everyday order ("Spitz - German Pomeranian" becomes "Pomeranian"). No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.